Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions
A Single-dose, Open Labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions
Sponsor: Jiangsu Furui Pharmaceuticals Co., Ltd
Listed as NCT01235156, this observational or N/A phase trial focuses on Premature Ventricular Contraction and remains ongoing. Sponsored by Jiangsu Furui Pharmaceuticals Co., Ltd, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: PHASE2 → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Furui Pharmaceuticals Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .